Clinical trials: Post-COVID-19 Condition
Burnout, Caregiver, Burnout, Professional
Frontline Clinician Psilocybin Study
This study aims to investigate the effects of a single dose of psilocybin, delivered in the contextof pre- and post-dose psychotherapy, on symptoms of depression and burnout suffered by healthcare clinicians as a result of…
- Conditions
- Burnout, Caregiver, Burnout, Professional, COVID-19, Depression
- Trial name
- NCT05163496
- Testing
- Psilocybin (Usona Institute)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
COVID-19, Corona Virus Infection
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons…
- Conditions
- COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
- Trial name
- NCT04328961
- Testing
- Hydroxychloroquine Sulfate, Ascorbic Acid
- Where
- 8 sites in United States
- Volunteers
- 943 people, healthy volunteers welcome
- Sponsor
- University of Washington
Post-acute COVID-19 Syndrome
Сlinical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.
The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial. The objective of this study is to evaluate the efficacy and safety of Prospekta in the treatment of asthenia in patients after the…
- Trial name
- NCT05074888
- Testing
- Prospekta
- Where
- 32 sites in Russia
- Volunteers
- 676 people
- Sponsor
- Materia Medica Holding
Post-COVID-19 Condition, Post-COVID-19 Syndrome
Vortioxetine for Post-COVID-19 Condition
A randomized, double-blinded, placebo-controlled trial will be conducted to evaluate vortioxetine, an antidepressant with established pro-cognitive properties, for the treatment of cognitive deficits which develop during or after…
- Conditions
- Post-COVID-19 Condition, Post-COVID-19 Syndrome, Cognitive Impairment
- Trial name
- NCT05047952
- Testing
- Vortioxetine
- Where
- Canada
- Volunteers
- 149 people
- Sponsor
- Brain and Cognition Discovery Foundation
Long COVID, Long COVID-19
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs…
- Conditions
- Long COVID, Long COVID-19, Long COVID19
- Trial name
- NCT05965752
- Testing
- BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE
- Where
- 24 sites in United States
- Volunteers
- 328 people
- Sponsor
- Duke University
COVID-19, Olfactory Disorder
Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction
This study will investigate the efficacy of oral gabapentin in olfactory improvement following Covid-19- associated olfactory dysfunction. This is a randomized, double-blinded, placebo-controlled trial.
- Conditions
- COVID-19, Olfactory Disorder, Anosmia, Hyposmia
- Trial name
- GRACE (NCT05184192)
- Testing
- Gabapentin gelatin capsules 300mg
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Washington University School of Medicine
Covid19
COVID-19 3rd Dose Vaccine in Transplant Patients
The purpose of this study is to investigate the efficient vaccine type as a booster dose for Coronavirus Disease of 2019 (COVID-19) in solid organ transplant recipients.
- Trial name
- NCT05047640
- Testing
- BNT162b2 vaccine, JNJ-78436735 Vaccine
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Giselle Guerra